congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Other/Multi
AMCP Nexus 2024 | October 14-17, 2024
A retrospective real-world evaluation of docetaxel-based treatments after standard of care (SOC) for patients with non-squamous (NSQ) advanced non-small cell lung cancer (aNSCLC)
Poster
Other/Multi
AMCP Nexus 2024 | October 14-17, 2024
Impact of delaying disease recurrence on economic burden in patients with HER2+ early-stage breast cancer (eBC)
Poster
Other/Multi
AMCP Nexus 2024 | October 14-17, 2024
Treatment patterns, clinical outcomes, and healthcare resource utilization (HRU) among patients with hormone receptor positive (HR+) HER2-low or IHC 0 metastatic breast cancer (mBC) – data from an integrated delivery network (IDN)